Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany

  • Background: Eligibility criteria are a critical part of clinical trials, as they define the patient population under investigation. Besides certain patient characteristics, clinical trials often include biomarker testing for eligibility. However, patient-identification mostly relies on the trial site itself and is often a time-consuming procedure, which could result in missing out on potentially eligible patients. Pre-selection of those patients using a registry could facilitate the process of eligibility testing and increase the number of identified patients. One aim with the PRAEGNANT registry (NCT02338167) is to identify patients for therapies based on clinical and molecular data. Here, we report eligibility testing for the SHERBOC trial using the German PRAEGNANT registry. Methods:Heregulin (HRG) has been reported to identify patients with better responses to therapy with the anti-HER3 monoclonal antibody seribantumab (MM-121). The SHERBOC trial investigated adding seribantumab (MM-121) to standard therapy in patients with advanced HER2-negative, hormone receptor–positive (HR-positive) breast cancer and HRG overexpression. The PRAEGNANT registry was used for identification and tumor testing, helping to link potential HRG positive patients to the trial. Patients enrolled in PRAEGNANT have invasive and metastatic or locally advanced, inoperable breast cancer. Patients eligible for SHERBOC were identified by using the registry. Study aims were to describe the HRG positivity rate, screening procedures, and patient characteristics associated with inclusion and exclusion criteria. Results: Among 2769 unselected advanced breast cancer patients, 650 were HER2-negative, HR-positive and currently receiving first- or second-line treatment, thus potentially eligible for SHERBOC at the end of current treatment; 125 patients also met further clinical eligibility criteria (e.g. menopausal status, ECOG). In the first/second treatment lines, patients selected for SHERBOC based on further eligibility criteria had a more favorable prognosis than those not selected. HRG status was tested in 38 patients, 14 of whom (36.8%) proved to be HRG-positive. Conclusion: Using a real-world breast cancer registry allowed identification of potentially eligible patients for SHERBOC focusing on patients with HER3 overexpressing, HR-positive, HER2-negative metastatic breast cancer. This approach may provide insights into differences between patients eligible or non-eligible for clinical trials. Trial registration: Clinicaltrials, NCT02338167, Registered 14 January 2015 - retrospectively registered.

Download full text files

Export metadata

Additional Services

Share in Twitter Search Google Scholar
Author:Hanna Hübner, Christian M. KurbacherGND, Geoffrey Kuesters, Andreas D. Hartkopf, Michael P. Lux, Jens HuoberGND, Bernhard Volz, Florin-Andrei ŢăranORCiDGND, Friedrich Overkamp, Hans TeschORCiDGND, Lothar HäberleORCiD, Diana LüftnerORCiDGND, Markus Wallwiener, Volkmar MüllerORCiDGND, Matthias Wilhelm BeckmannORCiDGND, Erik Belleville, Matthias Rübner, Michael UntchORCiDGND, Peter Andreas FaschingORCiDGND, Wolfgang JanniORCiDGND, Tanja FehmORCiDGND, Hans-Christian KolbergGND, Diethelm Wallwiener, Sara Y. Brucker, Andreas SchneeweissORCiDGND, Johannes Ettl
Parent Title (English):BMC Cancer
Publisher:BioMed Central
Document Type:Article
Date of Publication (online):2020/11/11
Date of first Publication:2020/11/11
Publishing Institution:Universitätsbibliothek Johann Christian Senckenberg
Release Date:2020/11/24
Tag:Advanced breast cancer; Antihormone therapy; Heregulin; MM-121; Metastatic; Seribantumab
Issue:Art. 1091
Page Number:13
Institutes:Medizin / Medizin
Dewey Decimal Classification:6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit
Licence (German):License LogoCreative Commons - Namensnennung 4.0